THERAPY DOSSIER · th-521b2db1368c

Zhenbao pill, a traditional Mongolian and Chinese polyherbal preparation

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06049498 ↗NAcompleted

Efficacy and Safety of Mongolian Medicine ZhenBao Pills on Limb Function Recovery After Acute Ischemic Stroke

Ischemic Stroke

Enrolment: 216 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29187582 ↗2018Reported benefit

Zhenbao pill protects against acute spinal cord injury via regulating the expression of GPR17.

RatSpinal cord injuryContusionSprague-DawleyFemalen = 49 rats total: first experiment n=21 in three groups of 7,…Intragastric oral gavage0.6 g/kg/day, selected from a dose range of 0.2, 0.4, 0.6 a…After induction of acute spinal cord injury; exact interval not stated

Model: Acute spinal cord injury by modified Allen weight-drop: laminectomy at T10, contusion with a 2.4 mm diameter impactor and 10 g weight dropped from 2.5 cm

Zhenbao pill improved hindlimb locomotor scores at all time points, reduced neuronal apoptosis and inflammatory mediators, raised the targeting microRNA and lowered GPR17, and these benefits were reversed by the microRNA inhibitor

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…